Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.
Company Details
- Employees
- 18
- Founded
- 2009
- Address
- Scheelevägen, Lund,skåne 22381,sweden
- Phone
- 556780-3480
- in****@****tela.se
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- xintela.se
- HQ
- Lund, Skåne
Xintela Ab Questions
Xintela Ab's helpline number is 556780-3480
Xintela Ab's website is xintela.se
Xintela Ab's LinkedIn profile is https://se.linkedin.com/company/xintela-ab
Xintela Ab has
18 employees.
View email and phone details for 18
employees at Xintela Ab.
Xintela Ab's industry is
Biotechnology Research
Xintela Ab's top competitors are
Rechon Life Science Ab,
Hansa Biopharma,
Galenica Ab,
Alligator Bioscience Ab,
Bioinvent International Ab,
Probi Ab,
Immunovia Ab,
Genovis,
Camurus,
Cantargia Ab.
Xintela Ab's support email address is info@xintela.se
Xintela Ab's categories are Biotechnology Research
Xintela Ab's founding year is 2009
